Platelet Rich Plasma (PRP) is a blood plasma product in which concentration of platelets and growth factors is elevated four to eight times than normal blood platelet concentration. Platelet rich plasma is also called as platelet rich gel, platelet enriched plasma or platelet enriched gel. PRP is an effective treatment to treat various diseases such as orthopedic diseases, sports injuries, neurological diseases and cardiothoracic diseases, minor injuries that require outpatient surgeries. Platelet rich plasma therapy has been extensively used in various applications in cosmetic industry as an anti-aging therapy for skin rejuvenation, wrinkle reduction, skin tightening.
The global platelet rich plasma market report provides market size (Revenue USD Million 2014 to 2021), market share and forecasts growth trends (CAGR%, 2017 to 2021).
The global platelet rich plasma market segmentation is based on product types (leukocyte-platelet rich fibrin, leukocyte-platelet rich plasma, pure-platelet rich plasma), source types (allogenic, autologus, homologus), and applications (cosmetic surgery, general surgery, neurosurgery, orthopedic surgery, and surgeries like oral and maxillofacial, cardiothoracic, periodontal, urological).
The global platelet rich plasma market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market and provides analysis of the company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market. The global platelet rich plasma market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global platelet rich plasma market and included in this report are AdiStem Ltd., Arteriocyte Medical Systems, Inc., Arthrex, Inc., Biomet, Inc., Cesca Therapeutics, Inc., DePuy Synthes, Inc., Dr. PRP America LLC., EmCyte Corporation, Exactech, Inc., Harvest Technologies Corp., Nuo Therapeutics, Inc., Regen Lab SA, and Stryker Corporation.